RC
CYCN icon

Rangeley Capital’s Cyclerion Therapeutics CYCN Stock Holding History

Rangeley Capital’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.4K Buy
+24,310
New +$78.9K 0.08% 155

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $140M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rangeley Capital's CYCN Position: Q2 2026 in Review

Rangeley Capital opened a new position in Cyclerion Therapeutics (CYCN) in Q2 2026: 24,310 shares worth $82.4K. The stake represents 0.08% of the portfolio and ranks #155 among its holdings.

21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Rangeley Capital held 24,310 shares of Cyclerion Therapeutics worth $82.4K as of Q2 2026.
  • Cyclerion Therapeutics was a new Rangeley Capital position in Q2 2026.
  • Cyclerion Therapeutics made up 0.08% of Rangeley Capital's portfolio in Q2 2026, its #155 holding.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.